Dopamine Receptor Variants and Schizophrenia in South India
Author Information
Author(s): Vijayan Neetha N, Bhaskaran Sujatha, Koshy Linda V, Natarajan Chandrasekhar, Srinivas Lekshmy, Nair Chandrasekharan M, Allencherry Priya M, Banerjee Moinak
Primary Institution: Human Molecular Genetics Laboratory, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India
Hypothesis
The study investigates the association of dopamine receptor polymorphisms with schizophrenia and treatment response in a South Indian population.
Conclusion
Certain polymorphisms in the DRD2 gene are associated with schizophrenia and treatment response in the South Indian population.
Supporting Evidence
- H313HTT genotype was associated with schizophrenia (P = 0.004).
- TaqIB1B1 genotype was significantly associated with higher psychopathology scores.
- Certain genotypes showed higher mean improvement scores in treatment response.
- Distinct shifts in linkage disequilibrium patterns were observed between responders and non-responders.
Takeaway
This study looks at how specific genes related to dopamine affect schizophrenia and how well patients respond to treatment in South India.
Methodology
The study involved 213 patients and 196 controls, examining various DRD2 gene polymorphisms and their association with schizophrenia and treatment response.
Potential Biases
Potential ethnic bias in the sample population may limit the generalizability of the findings.
Limitations
The study did not control for medication types and dosages, which may affect treatment response.
Participant Demographics
213 patients (81 males, 132 females) with a mean age of 34.40 years.
Statistical Information
P-Value
0.004
Confidence Interval
1.212 to 2.911
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website